ABSTRACT
BackgroundA new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic.AimWe aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework.MethodsData of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework.ResultsThe new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives.ConclusionThe new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.
Subject(s)
COVID-19 , Influenza, Human , Pandemics , Respiratory Syncytial Virus Infections , SARS-CoV-2 , World Health Organization , Humans , COVID-19/epidemiology , Israel/epidemiology , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Infections/diagnosis , Influenza, Human/epidemiology , Influenza, Human/diagnosis , Sentinel Surveillance , Laboratories, Hospital/statistics & numerical data , Respiratory Syncytial Virus, Human/isolation & purification , Population Surveillance/methodsABSTRACT
The prevalence of tuberculosis (TB) and human immunodeficiency virus (HIV) coinfection in Nigeria is currently around 19.1%. This indicates that the two diseases are still a burden on the nation"s health. The aim of this study was to evaluate the diagnostic microbiology capacity and the barriers in performing assay for TB and HIV at peripheral district-level hospital-based laboratories in Oyo State, Nigeria. Diagnostic microbiology capacity was estimated using a scale of 100-point where scores ≤ 49% were categorized as low, 50-79% fair and ≥80% good. Barriers to diagnosis were summarized in proportions. The diagnostic microbiology capacity revealed that 6 (35.3%) and 11 (64.7%) of the laboratories had "fair" and "low" capacity, respectively, to detect TB in cerebrospinal fluid/sputum. In testing for HIV, 3 (17.6%) of the laboratories had "fair capacity" and 14 (82.4%) had "low capacity" to detect CD4 count and HIV antibodies in blood serum. The major diagnostic barriers in almost all (94.1%) the laboratories were lack of culture supplies and nonavailability of reagents/testing kits. There was no diagnostic microbiology service with good capacity to facilitate case detection of HIV and TB at the peripheral hospitals. Hence there is a need to improve the supply of reagents, culture stock and testing kits. This will facilitate the detection of TB and HIV cases in peripheral communities. IMPORTANCE This study provided a snapshot knowledge of testing capabilities and commodity availability at state laboratories. The findings should inform the action of stakeholders to improve diagnostic microbiology capacity, consequently enhancing diagnostic measures in detecting human immunodeficiency virus and Mycobacterium tuberculosis.
Subject(s)
Coinfection/diagnosis , HIV Infections/diagnosis , Laboratories, Hospital/standards , Tuberculosis, Pulmonary/diagnosis , Adult , Antibodies, Viral/blood , Coinfection/epidemiology , Coinfection/microbiology , Coinfection/virology , Female , HIV Infections/blood , HIV Infections/epidemiology , HIV Infections/virology , HIV-1/genetics , HIV-1/isolation & purification , Humans , Laboratories, Hospital/statistics & numerical data , Laboratory Personnel/standards , Male , Middle Aged , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Nigeria/epidemiology , Sputum/microbiology , Tuberculosis, Pulmonary/microbiologyABSTRACT
OBJECTIVES: To quantify the workload and cost overload that the COVID-19 pandemic has meant for a Clinical Microbiology laboratory in a real-life scenario. METHODS: We compared the number of samples received, their distribution, the human resources, and the budget of a Microbiology laboratory in the COVID pandemic (March-December 2020) with the same months of the previous year. RESULTS: the total number of samples processed in the Clinical Microbiology laboratory in March to December 2020 increased 96.70% with respect to 2019 (from 246,060 to 483,993 samples), reflecting an increment of 127.50% when expressed as samples/1000 admissions (from 6057 to 13,780). The increase in workload was mainly at the expense of the virology (+2058%) and serology (+86%) areas. Despite additional personnel hiring, the samples processed per technician increased 12.5%. The extra cost attributed to Microbiology amounts to 6,616,511 euros (114.8%). CONCLUSIONS: This is the first study to provide quantitative figures about workload and cost increase caused by the COVID-19 in a Microbiology laboratory.
Subject(s)
COVID-19/epidemiology , Laboratories, Hospital/statistics & numerical data , COVID-19/diagnosis , COVID-19/economics , COVID-19 Testing/economics , COVID-19 Testing/statistics & numerical data , Clinical Laboratory Services/economics , Clinical Laboratory Services/statistics & numerical data , Costs and Cost Analysis , Hospitalization/statistics & numerical data , Humans , Laboratories, Hospital/economics , Medical Laboratory Personnel/economics , Medical Laboratory Personnel/statistics & numerical data , SARS-CoV-2/isolation & purification , Spain/epidemiology , Tertiary Care Centers , Workload/statistics & numerical dataABSTRACT
Desde el inicio de la pandemia de COVID-19, el Laboratorio de Virología del Hospital Garrahan, implementó el diagnóstico molecular de SARS-CoV-2 mediante RT-PCR para dar respuesta rápida y de calidad a la creciente demanda. Al diagnóstico pediátrico se sumó el diagnóstico de los padres / acompañantes y personal de salud con criterio de caso sospechoso. Al inicio del 2021 se incorporó el test rápido de detección de antígeno para pacientes sintomáticos. Hasta junio de 2021 se procesó un total de 58 000 muestras para estudios moleculares. (AU)
Since the beginning of the COVID-19 pandemic, the Virology Laboratory of Garrahan Hospital has implemented molecular diagnosis of SARS-CoV-2 using RT-PCR in order to provide a rapid and high-quality response to the growing demand. In addition to the pediatric diagnosis, the diagnosis of parents/companions and healthcare personnel meeting the criteria of a suspected case was also added. At the beginning of 2021, the rapid antigen detection test for symptomatic patients was incorporated. Until June 2021, a total of 58,000 samples were analyzed by molecular studies. (AU)
Subject(s)
Humans , Laboratories, Hospital/statistics & numerical data , Molecular Diagnostic Techniques , COVID-19 Nucleic Acid Testing , COVID-19 Serological Testing , SARS-CoV-2/isolation & purification , COVID-19/diagnosis , PandemicsABSTRACT
INTRODUCTION: Following a pandemic, laboratory medicine is vulnerable to laboratory errors due to the stressful and high workloads. We aimed to examine how laboratory errors may arise from factors, e.g., flexible working order, staff displacement, changes in the number of tests, and samples will reflect on the total test process (TTP) during the pandemic period. MATERIALS AND METHODS: In 12 months, 6 months before and during the pandemic, laboratory errors were assessed via quality indicators (QIs) related to TTP phases. QIs were grouped as pre-, intra- and postanalytical. The results of QIs were expressed in defect percentages and sigma, evaluated with 3 levels of performance quality: 25th, 50th and 75th percentile values. RESULTS: When the pre- and during pandemic periods were compared, the sigma value of the samples not received was significantly lower in pre-pandemic group than during pandemic group (4.7σ vs. 5.4σ, P = 0.003). The sigma values of samples transported inappropriately and haemolysed samples were significantly higher in pre-pandemic period than during pandemic (5.0σ vs. 4.9σ, 4.3σ vs. 4.1σ; P = 0.046 and P = 0.044, respectively). Sigma value of tests with inappropriate IQC performances was lower during pandemic compared to the pre-pandemic period (3.3σ vs. 3.2σ, P = 0.081). Sigma value of the reports delivered outside the specified time was higher during pandemic than pre-pandemic period (3.0σ vs. 3.1σ, P = 0.030). CONCLUSION: In all TTP phases, some quality indicators improved while others regressed during the pandemic period. It was observed that preanalytical phase was affected more by the pandemic.
Subject(s)
COVID-19/epidemiology , Laboratories, Hospital/statistics & numerical data , Quality Indicators, Health Care/statistics & numerical data , COVID-19/pathology , COVID-19/virology , Diagnostic Errors/statistics & numerical data , Humans , Pandemics , Quality Indicators, Health Care/standards , SARS-CoV-2/isolation & purification , Turkey/epidemiologyABSTRACT
OBJECTIVES: Pathology services are limited in most areas of sub-Saharan Africa. This study's aim was to survey anatomic and clinical pathology services and laboratory infrastructure in Mozambique. METHODS: A survey was conducted from October-December 2018 across the four central hospitals of Mozambique to determine infrastructure and pathology services available. RESULTS: Most laboratory/pathology services in Mozambique are limited to the four central hospitals. Only 14 pathologists practice in the country despite a population of 29.5 million for the world's fifth worst workforce/population ratio. Approximately 35,000 anatomic pathology specimens are evaluated annually. Standard services across chemistry, hematology, microbiology, and blood bank are available at the four central hospitals. Esoteric laboratory testing and immunohistochemistry are generally only available in Maputo. CONCLUSIONS: While most pathology services are available in Mozambique, many are available only at the Maputo laboratory. Expansion of pathology services and infrastructure will improve provision of effective and efficient health care as access to timely and accurate clinical diagnoses increases in Mozambique.
Subject(s)
Laboratories, Hospital/statistics & numerical data , Pathologists/statistics & numerical data , Pathology, Clinical/statistics & numerical data , Developing Countries , Humans , Mozambique , Surveys and QuestionnairesABSTRACT
BACKGROUND: To the authors' knowledge, the impact of the coronavirus disease 2019 (COVID-19) pandemic on cytopathology practices worldwide has not been investigated formally. In the current study, data from 41 respondents from 23 countries were reported. METHODS: Data regarding the activity of each cytopathology laboratory during 4 weeks of COVID-19 lockdown were collected and compared with those obtained during the corresponding period in 2019. The overall number and percentage of exfoliative and fine-needle aspiration cytology samples from each anatomic site were recorded. Differences in the malignancy and suspicious rates between the 2 periods were analyzed using a meta-analytical approach. RESULTS: Overall, the sample volume was lower compared with 2019 (104,319 samples vs 190,225 samples), with an average volume reduction of 45.3% (range, 0.1%-98.0%). The percentage of samples from the cervicovaginal tract, thyroid, and anorectal region was significantly reduced (P < .05). Conversely, the percentage of samples from the urinary tract, serous cavities, breast, lymph nodes, respiratory tract, salivary glands, central nervous system, gastrointestinal tract, pancreas, liver, and biliary tract increased (P < .05). An overall increase of 5.56% (95% CI, 3.77%-7.35%) in the malignancy rate in nongynecological samples during the COVID-19 pandemic was observed. When the suspicious category was included, the overall increase was 6.95% (95% CI, 4.63%-9.27%). CONCLUSIONS: The COVID-19 pandemic resulted in a drastic reduction in the total number of cytology specimens regardless of anatomic site or specimen type. The rate of malignancy increased, reflecting the prioritization of patients with cancer who were considered to be at high risk. Prospective monitoring of the effect of delays in access to health services during the lockdown period is warranted.
Subject(s)
COVID-19/prevention & control , Communicable Disease Control/standards , Laboratories, Hospital/statistics & numerical data , Pathology, Clinical/statistics & numerical data , Workload/statistics & numerical data , Biopsy, Fine-Needle/statistics & numerical data , COVID-19/epidemiology , COVID-19/virology , Humans , Laboratories, Hospital/trends , Pathology, Clinical/trends , SARS-CoV-2/pathogenicity , Societies, Medical/statistics & numerical data , Surveys and Questionnaires/statistics & numerical dataABSTRACT
BACKGROUND: The purpose of the current study was to examine the impact of coronavirus disease 2019 (COVID-19) on various aspects of cytology practice in the Asia-Pacific region. METHODS: An online questionnaire was distributed to cytopathology laboratories in 24 Asia-Pacific countries to explore the impact of restrictive measures on access to health care, use of general and personal protective equipment (PPE), and changes in cytology workflow and workload from February to April 2020. RESULTS: A total of 167 cytopathology laboratories from 24 countries responded to the survey; the majority reported that restrictive measures that limited the accessibility of health care services had been implemented in their cities and/or countries (80.8%) and their hospitals (83.8%). The respondents noted that COVID-19 had an impact on the cytologic workflow as well as the workload. Approximately one-half of the participants reported the implementation of new biosafety protocols (54.5%) as well as improvements in laboratory facilities (47.3%). Rearrangement or redeployment of the workforce was reported in 53.3% and 34.1% of laboratories, respectively. The majority of the respondents reported a significant reduction (>10%) in caseload associated with both gynecological (82.0%) and nongynecological specimens (78.4%). Most laboratories reported no significant change in the malignancy rates of both gynecological (67.7%) and nongynecological specimens (58.7%) compared with the same period in 2019. CONCLUSIONS: The results of the survey demonstrated that the COVID-19 pandemic resulted in a significant reduction in the number of cytology specimens examined along with the need to implement new biosafety protocols. These findings underscore the need for the worldwide standardization of biosafety protocols and cytology practice.
Subject(s)
COVID-19/prevention & control , Communicable Disease Control/standards , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Laboratories, Hospital/organization & administration , Pathology, Clinical/organization & administration , Asia , COVID-19/epidemiology , COVID-19/transmission , COVID-19/virology , Communicable Disease Control/instrumentation , Health Workforce/organization & administration , Health Workforce/standards , Health Workforce/statistics & numerical data , Humans , Laboratories, Hospital/standards , Laboratories, Hospital/statistics & numerical data , Pacific States , Pandemics/prevention & control , Pathology, Clinical/standards , Pathology, Clinical/statistics & numerical data , Personal Protective Equipment/standards , SARS-CoV-2/pathogenicity , Surveys and Questionnaires/statistics & numerical data , Workload/statistics & numerical dataSubject(s)
Betacoronavirus , Cardiology , Cardiovascular Diseases/diagnosis , Coronavirus Infections/diagnosis , Laboratories, Hospital/statistics & numerical data , Pandemics , Pneumonia, Viral/diagnosis , COVID-19 , Cardiovascular Diseases/complications , Coronavirus Infections/complications , Coronavirus Infections/epidemiology , Humans , Pneumonia, Viral/complications , Pneumonia, Viral/epidemiology , SARS-CoV-2ABSTRACT
Retrospective chart review of all children (aged-one month to 16 years) admitted in our paediatric intensive care from June to November 2016 was done to determine the indication of different laboratory tests. LBT indications were defined into: diagnostic/case findings/screening tests to make a diagnosis; haemostatic tests (to monitor function or identify before clinical signs and symptoms) and therapeutic /monitoring tests to get the level of drug directly or getting level of marker as a guide to therapy. Laboratory tests reports which were within normal range more than once were labelled as in-appropriate tests. In total 274 patients, Haemostatic tests were performed for mean of 35.18±56.72 times (range of 0-429), monitoring for mean of 9.38±20 times (range 0-165), and therapeutic tests (3.26±11.25). Most common tests included serum Sodium levels (7.83±12.73), Serum Potassium (8.19±12.80), bicarbonate (7.75±11.9). 13.40±9.11 tests were done on first day and 13.0±8.49/day tests were performed afterwards. Cumulatively 54.31±74.21 tests were performed/ patients out of which 18.5±37.82 were inappropriate.
Subject(s)
Blood Chemical Analysis/statistics & numerical data , Intensive Care Units, Pediatric , Laboratories, Hospital/statistics & numerical data , Unnecessary Procedures/statistics & numerical data , Adolescent , Child , Child, Preschool , Humans , Infant , Retrospective StudiesABSTRACT
Objectives: The new European In Vitro Diagnostic (IVD) Regulation 2017/746 (IVDR) restricts the use of lab-developed tests (LDT) after 26th May 2022. There are no data on the impact of the IVDR on laboratories in the European Union. Methods: Laboratory tests performed in UZ Leuven were divided in four groups: core laboratory, immunology, special chemistry, and molecular microbiology testing. Each test was classified as Conformité Européenne (CE)-IVD, modified/off-label CE-IVD, commercial Research Use Only (RUO) or LDT. Each matrix was considered a separate test. Results: We found that 97.6% of the more than 11.5 million results/year were generated with a CE-IVD method. Of the 922 different laboratory tests, however, only 41.8% were CE-IVD, 10.8% modified/off-label CE-IVD, 0.3% RUO, and 47.1% LDT. Off-label CE-IVD was mainly used to test alternative matrices not covered by the claim of the manufacturer (e.g., pleural or peritoneal fluid). LDTs were mainly used for special chemistry, flow cytometry, and molecular testing. Excluding flow cytometry, the main reasons for the use of 377 LDTs were lack of a CE-IVD method (71.9%), analytical requirements (14.3%), and the fact the LDT was in use before CE-IVD available (11.9%). Conclusions: While the large majority of results (97.6%) were generated with a CE-IVD method, only 41.8% of laboratory tests were CE-IVD. There is currently no alternative on the market for 71.5% of the 537 LDTs performed in our laboratory which do not fall within the scope of the current IVD directive (IVDD). Compliance with the IVDR will require a major investment of time and effort.
Subject(s)
Hospitals, University/standards , Laboratories, Hospital/standards , Reagent Kits, Diagnostic/standards , Belgium , Chemistry Techniques, Analytical/standards , Chemistry Techniques, Analytical/statistics & numerical data , Hospitals, University/legislation & jurisprudence , Hospitals, University/statistics & numerical data , Humans , Immunologic Tests/standards , Immunologic Tests/statistics & numerical data , Laboratories, Hospital/legislation & jurisprudence , Laboratories, Hospital/statistics & numerical data , Microbiological Techniques/standards , Microbiological Techniques/statistics & numerical data , Reagent Kits, Diagnostic/statistics & numerical dataABSTRACT
Laboratories need to set up effective overall management of their internal quality control (IQC) and external quality assessment (EQA) results as key elements in statistical process control. Quality targets need to be defined, with methods to ensure durable control with respect to the relevant specifications. The hemostasis laboratory of the Lyon Hospitals Board (HCL, Lyon, France) uses model 3 from the Milan consensus conference, which is the state of the art in terms of quality targets, and uses a common EQA provider supplying as many real patient samples as possible. Giving priority to adopted methods, the lab optimizes the use of manufacturers' prior data: maximum acceptable inter assay coefficient of variation (CV) and prior IQC target values. Bayesian inference brings the method under control with respect to the manufacturers' prior data without the need for a preliminary phase. It links the IQC and EQA plans by the maximum acceptable CVs defined by the manufacturer.
Subject(s)
Hematologic Tests/statistics & numerical data , Hematologic Tests/standards , Laboratories, Hospital/statistics & numerical data , Quality Assurance, Health Care , Bayes Theorem , Blood Coagulation Tests/instrumentation , Blood Coagulation Tests/methods , Blood Coagulation Tests/standards , Blood Coagulation Tests/statistics & numerical data , Clinical Laboratory Services/organization & administration , Clinical Laboratory Services/standards , Clinical Laboratory Services/statistics & numerical data , France/epidemiology , Hematologic Tests/instrumentation , Hematologic Tests/methods , Hemostasis/physiology , Humans , Laboratories, Hospital/organization & administration , Laboratories, Hospital/standards , Laboratory Proficiency Testing/organization & administration , Laboratory Proficiency Testing/standards , Laboratory Proficiency Testing/statistics & numerical data , Professional Practice/organization & administration , Professional Practice/standards , Professional Practice/statistics & numerical data , Quality Assurance, Health Care/methods , Quality Assurance, Health Care/organization & administration , Quality Assurance, Health Care/standards , Quality Assurance, Health Care/statistics & numerical data , Quality Control , Retrospective StudiesABSTRACT
Objectives: The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 conducted a global survey to understand how biochemistry laboratories manage the operational challenges during the coronavirus disease 2019 (COVID-19) pandemic. Materials and methods: An electronic survey was distributed globally to record the operational considerations to mitigate biosafety risks in the laboratory. Additionally, the laboratories were asked to indicate the operational challenges they faced. Results: A total of 1210 valid submissions were included in this analysis. Most of the survey participants worked in hospital laboratories. Around 15% of laboratories restricted certain tests on patients with clinically suspected or confirmed COVID-19 over biosafety concerns. Just over 10% of the laboratories had to restrict their test menu or services due to resource constraints. Approximately a third of laboratories performed temperature monitoring, while two thirds of laboratories increased the frequency of disinfection. Just less than 50% of the laboratories split their teams. The greatest reported challenge faced by laboratories during the COVID-19 pandemic is securing sufficient supplies of personal protective equipment (PPE), analytical equipment, including those used at the point of care, as well as reagents, consumables and other laboratory materials. This was followed by having inadequate staff, managing their morale, anxiety and deployment. Conclusions: The restriction of tests and services may have undesirable clinical consequences as clinicians are deprived of important information to deliver appropriate care to their patients. Staff rostering and biosafety concerns require longer-term solutions as they are crucial for the continued operation of the laboratory during what may well be a prolonged pandemic.
Subject(s)
Betacoronavirus , Coronavirus Infections/prevention & control , Laboratories, Hospital/organization & administration , Laboratories, Hospital/statistics & numerical data , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Surveys and Questionnaires , Body Temperature , COVID-19 , Containment of Biohazards/statistics & numerical data , Disease Outbreaks , Disinfection/statistics & numerical data , Health Workforce/organization & administration , Health Workforce/statistics & numerical data , Humans , Monitoring, Physiologic/statistics & numerical data , Personal Protective Equipment/statistics & numerical data , Risk Management/statistics & numerical data , SARS-CoV-2ABSTRACT
Objectives: A global survey was conducted by the IFCC Task Force on COVID-19 to better understand how general biochemistry laboratories manage the pre-analytical, analytical and post-analytical processes to mitigate biohazard risks during the coronavirus disease 2019 (COVID-19) pandemic. Methods: An electronic survey was developed to record the general characteristics of the laboratory, as well as the pre-analytical, analytical, post-analytical and operational practices of biochemistry laboratories that are managing clinical samples of patients with COVID-19. Results: A total of 1210 submissions were included in the analysis. The majority of responses came from hospital central/core laboratories that serve hospital patient groups and handle moderate daily sample volumes. There has been a decrease in the use of pneumatic tube transport, increase in hand delivery and increase in number of layers of plastic bags for samples of patients with clinically suspected or confirmed COVID-19. Surgical face masks and gloves are the most commonly used personal protective equipment (PPE). Just >50% of the laboratories did not perform an additional decontamination step on the instrument after analysis of samples from patients with clinically suspected or confirmed COVID-19. A fifth of laboratories disallowed add-on testing on these samples. Less than a quarter of laboratories autoclaved their samples prior to disposal. Conclusions: The survey responses showed wide variation in pre-analytical, analytical and post-analytical practices in terms of PPE adoption and biosafety processes. It is likely that many of the suboptimal biosafety practices are related to practical local factors, such as limited PPE availability and lack of automated instrumentation.
Subject(s)
Betacoronavirus , Coronavirus Infections/prevention & control , Laboratories, Hospital/statistics & numerical data , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Risk Management/statistics & numerical data , Surveys and Questionnaires , COVID-19 , Containment of Biohazards/statistics & numerical data , Disease Outbreaks , Humans , Infection Control/statistics & numerical data , Personal Protective Equipment/statistics & numerical data , SARS-CoV-2 , Specimen Handling/statistics & numerical dataSubject(s)
Laboratories, Hospital , Medical Errors/statistics & numerical data , Risk Management , Specimen Handling , Humans , Italy , Laboratories, Hospital/organization & administration , Laboratories, Hospital/statistics & numerical data , Medical Errors/prevention & control , Pilot Projects , Specimen Handling/methodsABSTRACT
The diagnosis of parasitic and fungal infections, historically based on the detection of these pathogens using direct diagnosis (macro/microscopic examination, culture) or serological methods, has considerably evolved in the last decades, especially with the development of molecular approaches and mass spectrometry. These techniques, as well as most analyses of parasitic and fungal serology, are mostly the preserve of Hospital University Centers Parasitology-Mycology laboratories. In 2016, the French association of medical parasitology and mycology teachers and hospital practitioners (Anofel) has provided a Catalogue of rare analyses, regularly updated and freely accessible on the Anofel website (https://anofel.net/). This tool, which hinges on 4 parts (parasitology, parasitic serology, mycology, and fungal serology), aims to provide information on all available analyses, and a list of hospital laboratories able to undertake them. It is complementary to the other reference works that were developed by our association, including the Guide of analyses and methods in parasitology and mycology, published in 2018, and the eANOFEL pictures and videos database, freely accessible online (http://www.eanofel.fr). In this article, we draw-up a state-of-the-art of the most specialized techniques available in the parasitology-mycology laboratories and presented in the Catalogue of rare analyses of the Anofel collegium, and their interest for the diagnosis of these infections.
Subject(s)
Diagnostic Techniques and Procedures , Mycology/methods , Mycoses/diagnosis , Parasitic Diseases/diagnosis , Parasitology/methods , Clinical Laboratory Services/standards , Clinical Laboratory Services/statistics & numerical data , Diagnostic Techniques and Procedures/trends , Humans , Laboratories, Hospital/standards , Laboratories, Hospital/statistics & numerical data , Mycology/trends , Mycoses/microbiology , Parasitic Diseases/parasitology , Parasitology/trendsABSTRACT
INTRODUCTION: Quality of care is essential to save people living with different diseases. However, inappropriate diagnosis may in no case lead to proper patient management as well as to quality of care. We conducted a cross-sectional descriptive analysis in three laboratories at the General Hospitals in the Democratic Republic of the Congo. METHODS: A team of national experts in the field of laboratories conducted a survey in the three clinical laboratories of the General Hospitals in the Democratic Republic of the Congo. Observations, visits and structured interviews using a questionnaire were used to assess the performance of these clinical laboratories. We also used a national evaluation guidance for the assessment of laboratories. RESULTS: The clinical laboratories of the General Hospitals visited showed many deficits, in particular, in infrastructures, in the basic and continuous training of the personnel, in the equipment, in supervision and quality control. Technical performances of these laboratories were not adapted to meet the needs of the population with regard to diseases frequently encountered in these areas. We also noted that these laboratories are little or almost not assisted and that there was no coordination team dedicated to the supervision and the assessment of laboratories in the hospital or even in the health zone. In addition, technicians working in their different laboratories had not been supervised over many years. CONCLUSION: Clinical laboratory improvement would allow for proper diagnosis of different diseases. This improvement should take into account local diseases. Within the system, it is important to devote more attention to clinical laboratories. Advocacy for this neglected component of the health system is necessary, as this situation could be the same in many developing countries.
Subject(s)
Hospitals, Rural , Laboratories, Hospital/organization & administration , Laboratories, Hospital/standards , Quality of Health Care , Clinical Laboratory Services/organization & administration , Clinical Laboratory Services/standards , Clinical Laboratory Services/statistics & numerical data , Cross-Sectional Studies , Democratic Republic of the Congo/epidemiology , Developing Countries , Equipment and Supplies, Hospital/standards , Equipment and Supplies, Hospital/statistics & numerical data , Equipment and Supplies, Hospital/supply & distribution , Hospitals, Rural/organization & administration , Hospitals, Rural/standards , Hospitals, Rural/statistics & numerical data , Humans , Laboratories, Hospital/statistics & numerical data , Patient Safety/standards , Quality Control , Quality of Health Care/organization & administration , Quality of Health Care/standards , Quality of Health Care/statistics & numerical dataABSTRACT
METHODS: We evaluated therapeutic TAT for a tertiary hospital in Western Kenya, using a time-motion study focusing specifically on common hematology and biochemistry orders. The aim was to determine significant bottlenecks in diagnostic testing processes at the institution. RESULTS: A total of 356 (155 hematology and 201 biochemistry) laboratory tests were fully tracked from the time of ordering to availability of results to care providers. The total therapeutic TAT for all tests was 21.5 ± 0.249 hours (95% CI). The therapeutic TAT for hematology was 20.3 ± 0.331 hours (95% CI) while that for biochemistry tests was 22.2 ± 0.346 hours (95% CI). Printing, sorting and dispatch of the printed results emerged as the most significant bottlenecks, accounting for up to 8 hours of delay (Hematology-8.3 ± 1.29 hours (95% CI), Biochemistry-8.5 ± 1.18 hours (95% CI)). Time of test orders affected TAT, with orders made early in the morning and those in the afternoon experiencing the most delays in TAT. CONCLUSION: Significant inefficiencies exist at multiple steps in the turnaround times for routine laboratory tests at a large referral hospital within an LMIC setting. Multiple opportunities exist to improve TAT and streamline processes around diagnostic testing in this and other similar settings.
Subject(s)
Laboratories, Hospital/statistics & numerical data , Quality Assurance, Health Care , Tertiary Care Centers/statistics & numerical data , Humans , Kenya , Time Factors , WorkflowABSTRACT
Fungal infections cause substantial morbidity and mortality. However, the burden of deep fungal infections is not well described in Uganda. We aimed to estimate the burden and etiology of histologically diagnosed deep fungal infections in Uganda. We retrospectively reviewed histology reports at the Pathology Reference Laboratory, Department of Pathology, Makerere University, Kampala, Uganda from January 1950 to September 2019 to identify any reports that had a fungal infection as the diagnosis. Over the study period, 697 cases of deep fungal infections were identified with an average incidence of 0.73/100,000 persons per decade. There was a general decline in the number of cases detected. Median age of the cases was 28 years (IQR: 11-40) and majority (59%) were male. The age group of 0-10 years were the most affected. The foot was the most affected part of the body (26%). Deep mycoses identified include eumycetoma (32%), subcutaneous phycomycosis (26%), histoplasmosis (9.2%), chromoblastomycosis (4.6%), aspergillosis (3.3%), cryptococcosis (3.3%), blastomycosis (1.6%), subcutaneous mycosis (1.4%), dermatomycosis (1.3%), coccidioidomycosis (0.6%), mucormycosis (0.6%), and sporotrichosis (0.1%). Histoplasma was the commonest causative agent (9.2%) followed by Aspergillus (3.4%) and Cryptococcus (3.3%), while 81% of the fungal pathogens were not identified to genus/species level. Only 31% of the cases were diagnosed clinically as deep fungal infections. There is a substantial burden of deep fungal infections caused by multiple fungal pathogens in Uganda. There is need to build local capacity for mycology so as to improve on the index of clinical suspicion and diagnostic capabilities.
Subject(s)
Invasive Fungal Infections/diagnosis , Invasive Fungal Infections/pathology , Adolescent , Adult , Child , Cost of Illness , Female , Fungi/classification , Fungi/isolation & purification , Fungi/pathogenicity , Humans , Incidence , Invasive Fungal Infections/epidemiology , Invasive Fungal Infections/microbiology , Laboratories, Hospital/statistics & numerical data , Male , Retrospective Studies , Uganda/epidemiology , Young AdultABSTRACT
BACKGROUND: Clinicians need to know timelines of requested laboratory tests to provide effective patient management. We developed a real-time laboratory progress checking system and measured its effectiveness using appropriate indicators in an emergency room setting. METHODS: In our original in-house health information system display, blank spaces, which were generated for test results when tests were ordered, remained empty until the final results reported. We upgraded the laboratory reporting system to show real-time testing information. The stages included requests for test, label printing, sampling, laboratory receipts, performance of tests, verification of results, and interpretation of results and final report by laboratory physician. To assess the usefulness of the function, we measured the emergency department healthcare workers' satisfaction and compared the number of phone calls about test status before and after implementation. RESULTS: After the system upgrade, the healthcare workers' understanding of the testing process increased significantly as follows. More clinicians could estimate the time of final test results through the real-time testing status information (61.9% and 85.7%, P = .002), and respondents reported that the upgraded system was more convenient than the original system (41.3% and 22.2%, respectively, P = .022). The number of phone calls about the test status decreased after implementation of the upgrade; however, the difference was not statistically significant (before, 0.13% [63 calls/48 637 tests] and after, 0.09% [42/46 666]; P = .066). CONCLUSIONS: The real-time display of laboratory testing status increased understanding of testing process among healthcare workers in emergency room, which ultimately may increase the usefulness and efficiency of the laboratory service use.